Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | RARA | P10276 | 3/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | RARG | P13631 | 3/20 | 0.46 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593759 | 0.92 | PTGS2 (0.79) | PTGS2PTGS1AOC3RARARARB | |
| SCHEMBL4592735 | 0.92 | PTGS2 (0.53) | PTGS2PTGS1AOC3CYP2C9 | |
| SCHEMBL8421061 | 0.86 | PTGS2 (0.88) | PTGS2PTGS1AOC3RARARARB | |
| SCHEMBL4668470 | 0.85 | PTGS2 (0.69) | PTGS2PTGS1AOC3RARARARB | |
| SCHEMBL6261746 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1AOC3RARARARB | |
| SCHEMBL4592500 | 0.83 | PTGS2 (0.47) | PTGS2PTGS1AOC3RARARARB | |
| SCHEMBL8420012 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1RARARARBRARG | |
| SCHEMBL8420266 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1RARARARBRARG | |
| SCHEMBL8423953 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1AOC3 | |
| SCHEMBL8423870 | 0.81 | PTGS2 (0.79) | PTGS2PTGS1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | claimed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1998056377-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | SCIOS INC. | 2006-01-26 | — | — | US | disclosed |
| US-20050129729-A1 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20040162289-A1 | Methods of promoting osteogenesis | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2004-08-19 | — | — | US | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019971-A1 | Treatment of cardiovascular disease with inhibitors of p38 kinase | MAPKAPK5, MAPK1, MAPKAPK2 | PTGS2 277/4885PTGS1 180/4885AOC3 2786/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | PTGS2 919/4885PTGS1 449/4885AOC3 1565/4885 |
| US-20040162289-A1 | Methods of promoting osteogenesis | MAPK1, BMP2, MAPK3 | PTGS2 919/4885PTGS1 449/4885AOC3 1565/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | PTGS2 70/4885PTGS1 47/4885AOC3 3847/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | PTGS2 70/4885PTGS1 47/4885AOC3 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.